Amarin Settlement Erodes Off-Label Promotion Enforcement
In an apparent first, the U.S. Food and Drug Administration has conceded that a pharmaceutical company may engage in truthful and nonmisleading speech promoting the off-label use of a prescription drug....To view the full article, register now.
Already a subscriber? Click here to view full article